Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
Published November 12, 2025 · Recall initiated: October 13, 2025
Summary
FDA records drug Class II recall D-0151-2026, published November 12, 2025 and initiated October 13, 2025. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Ongoing; Reported quantity: 4680 cartons; Lot: Lot # 100062316, Exp Date: 01/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Subpotent drug; Clavulanate Potassium component
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Distributor
- Distributed in three (3) States: MS, OH, CA.
- Lot
- Lot # 100062316, Exp Date: 01/2026
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMetoclopramide Tablets, USP, 5 mg, [100 or 500] Tablets per bottle, Rx Only, Manufactured for: TevaOctober 21, 2026
- FDAtraZODone Hydrochloride Tablets, USP, 50 mg, Rx only, 100 Tablets, Manufactured in Croatia By: Pliva HrvatskaSeptember 9, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kitsMay 13, 2026
- FDAClaravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10April 29, 2026
- FDAclomiPRAMINE Hydrochloride, Capsules, USP, 25 mg, packaged in a) 30-count bottles (NDC 16714-849-01), b)November 12, 2025
- FDAInitiation 3 Month Trial Tampon Box; Model Number: FG-TMP-MM-IB09090909;November 5, 2025
Questions about this recall
Was Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7. recalled?
Yes. FDA published recall D-0151-2026 on November 12, 2025. Reported hazard: Subpotent drug; Clavulanate Potassium component
What should I do if I have this product?
Voluntary: Firm initiated · Letter